ImmuPharma plc (LON:IMM – Get Free Report) was up 23.8% on Saturday . The company traded as high as GBX 5.70 ($0.07) and last traded at GBX 4.83 ($0.06). Approximately 16,731,404 shares traded hands during mid-day trading, a decline of 23% from the average daily volume of 21,725,510 shares. The stock had previously closed at GBX 3.90 ($0.05).
ImmuPharma Price Performance
The business has a 50 day simple moving average of GBX 2.46 and a 200 day simple moving average of GBX 1.95. The stock has a market cap of £20.11 million, a PE ratio of -483.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- 5 Top Rated Dividend Stocks to Consider
- 3 Volatility ETFs to Help You Profit from Market Chaos
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- Overbought Stocks Explained: Should You Trade Them?
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
